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610Fludarabine-Melphalan Conditioning for AML and MDS:
Alemtuzumab Reduces Acute and Chronic GVHD
without Affecting Long-Term Outcomes
Koen Van Besien,1 Rangesh Kunavakkam,2 Gaby Rondon,3 Marcos De Lima,3
Andrew Artz,1 Betul Oran,3 Sergio Giralt3The purpose of this study was to determine the effect of alemtuzumab on treatment-related mortality
(TRM), relapse, overall survival (OS), and disease-free survival (DSF) in patients with acute myelogenous leu-
kemia (AML) and myelodysplastic syndromes (MDS) undergoing reduced intensity conditioning (RIC). We
compared the outcome of 95 patients treated at the University of Chicago with fludarabine melphalan
(Flu 1 Mel) 1 alemtuzumab conditioning and 59 patients treated at the M.D. Anderson Cancer Center
with Flu 1 Mel conditioning. Both groups had similar patient and donor characteristics. There were no sig-
nificant differences in TRM, relapse, survival, and DFS between the 2 groups. The incidence of acute graft-
versus-host disease (aGVHD) grade II-IV (relative risk [RR] 5.5, P\ .01) and chronic GVHD (cGVHD)
(RR 6.6, P\.01) were significantly lower in patients receiving alemtuzumab. The addition of alemtuzumab
to an RIC regimen dramatically reduces the incidence of aGVHD and cGVHD in patients with AML and
MDS undergoing allogeneic transplantation. TRM, relapse risk, OS and DFS are not affected.
Biol Blood Marrow Transplant 15: 610-617 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Allogeneic transplant, AML, MDS, T cell depletion, AlemtuzumabINTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) offers the potential for prolonged disease-free
survival (DFS) for patients with advanced myelodys-
plastic syndrome (MDS) and acute myelogenous leu-
kemia (AML) [1-3]. However, such patients are often
older, have chemotherapy-resistant disease, have de-
creased performance status, suffer from comorbidities,
and lack related donors. With conventional total body
irradiation (TBI) or busulfan (Bu)-based conditioning
regimens followed by infusion of unmodified allo-
grafts, long-term survival rates range between 20%
and 50%. Modification of conditioning regimens and
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The M.D. Anderson group pioneered the use of
fludarabine melphalan (Flu 1 Mel) conditioning,
which has since gained wide usage [4-7]. The use of
high-doseMel for conditioning in allogeneic transplan-
tation is based on its convenience, its broad antitumor
activity in hematologic malignancies, and its immuno-
suppressive effects, initially described in animal models,
but subsequently confirmed by empirical clinical ob-
servations [8,9]. Flu was added to this conditioning
regimen because of its potent immunosuppressive
effects and its potential synergism with alkylators [10].
The Flu 1 Mel conditioning regimen results in
long-term survival of patients with advanced hemato-
logicmalignancies that is similar to that afterTBI-based
conditioning [4-7]. It is more efficacious than regimens
that are further reduced in intensity (RIC) [4], and less
toxic than combinations of Mel with 2CDA [11]. The
most limiting side effect of this conditioning regimen
is the high incidence of acute GVHD (aGVHD) and
particularly chronic GVHD (cGVHD). In a recent
M.D. Anderson series, the cumulative incidence of
cGVHDwas 49%, and cGVHDwas the primary cause
of death in 25%of patients [12]. Infections, often related
to GVHD or its treatment, accounted for another 10
deaths. Fatal regimen-related complications also occur
in 10% to 15% of patients receiving this conditioning
Biol Blood Marrow Transplant 15:610-617, 2009 611Fludarabine-Melphalan Conditioning for AML and MDSregimen. In vivoT cell depletion with alemtuzumab has
beenutilized in combinationwithFlu andMel to reduce
the incidence of severe aGVHD and cGVHD [13-17].
Posttransplant methotrexate (MTX), a cause ofmucosi-
tis and liver toxicity is usually omitted in those regimens.
Although the reduction in GVHD with alemtuzumab-
containing conditioning regimens is well documented,
there are concerns over increases in rates of disease re-
currence and over increased risks of opportunistic infec-
tions, particularly cytomegalovirus (CMV), because of
excessive immunocompromise [18,19]. To evaluate
the impact of alemtuzumab on complications and out-
come of allogeneic transplantation for AML andMDS,
we compared the outcomes of 59 patients prospectively
treated at the M.D. Anderson Cancer Center
(MDACC)with thatof 95patients treatedonaprospec-
tive study at the University of Chicago (UC).PATIENTS AND METHODS
All patients were treated on institutional protocols
approved by the local institutional review board. All
patients and donors provided written informed con-
sent. Patients at the UC were treated on a prospective
institutional protocol for patients with hematologic
malignancies. All patients with AML and MDS
accrued to this protocol between February 2002 and
October 2007 are included in this analysis. Fifty-seven
of these patients have been reported previously [20].
Patients from MDACC were those with AML or
high-risk MDS treated with the combination of
Flu 1 Mel and allogeneic HSCT using bone marrow
(BM) or peripheral blood progenitor cells (PBPCs).
These patients have been reported previously [12].
One transplant occurred in 1997 and 1 in 1998. The
remainder occurred between February 1999 and
December 2003.
For categorization of patients, the American Soci-
ety for Blood andMarrow Transplantation (ASBMT)/
Center for International Blood and Marrow Trans-
plant Research (CIBMTR) criteria of high-, interme-
diate-, and low-risk disease were used. Low-risk AML
patients are those in first complete remission (CR1).
Intermediate risk are those in second or third remis-
sion, and high risk are those with active disease at the
time of conditioning. For MDS patients, refractory
anemia (RA) and refractory anemia with ring sidero-
blasts (RARS) are considered low risk. All others are
considered high-risk disease.
Donor Typing and Stem Cell Source
At the UC, acceptable donors were related or
unrelated donors with no more than a 1-antigen
mismatch after considering HLA-A, -B, -C, and -DR.
Patients and donors for unrelated donor transplantation
were typed for theHLA -A, -B, -C, and -DR loci bymo-lecular sequencing techniques. At MDACC, acceptable
donors were related or unrelated, serologically matched
for HLA-A and -B, and matched for HLA-DRB1 by
high-resolution molecular methods. At the UC, gran-
ulocyte-colony stimulating factor (G-CSF) mobilized
peripheral blood stem cell (PBSC) collections were
preferred for both related and unrelated donors. At
MDACC, PBSC collections were preferred for re-
lated, and BM harvest for unrelated donors.
Preparative Regimen and GVHD Prophylaxis
Patients at the UC received Flu 30 mg/m2/day in-
travenously (i.v.), alemtuzumab 20 mg/day i.v. for 5
consecutive days (days –7, –6, –5, –4, and –3), and
Mel 140 mg/m2/day on day –2 . Acetaminophen, di-
phenhydramine, and methylprednisolone or hydrocor-
tisone were given to prevent alemtuzumab toxicity.
GVHD prophylaxis consisted of tacrolimus adjusted
to maintain blood levels of 5 to 15 ng/dL during the
first 100 days and then tapered as indicated depending
on donor type, and presence or absence of GVHD.
AtMDACC the conditioning regimen consisted of
Flu 25 to 30 mg/m2 for 4 to 5 days (transplant days26
or 25 to 22) with Mel 100 mg/m2 for patients trans-
planted in CR1 (n 5 13; 22%) or Mel 140 mg/m2 for
those with more advanced disease (n 5 46; 78%).
Fifty-three additional patients from MDACC who re-
ceived Mel 180 mg/m2 were not included because the
higher doses of Mel were associated with increased
treatment-related mortality (TRM). Mel was given
on day 22. Gemtuzumab ozogamicin 2 or 4 mg/m2
was added in 15 cases (day -12) [21]. Antithymocyte
globulin (ATG) was given to 20 patients receiving an
unrelated donor. GVHD prophylaxis consisted of
tacrolimus and MTX 5 mg/m2 i.v. on days 1, 3, 6,
and 11 after transplantation in all but 1 patient who
received cyclosporine (CsA). Tacrolimus doses were
adjusted to maintain blood levels of 5 to 15 ng/dL dur-
ing the first 100 days and then tapered as indicated
depending on donor type, presence, or absence of
GVHD.
Infection Prophylaxis and Supportive Care
At the UC, patients who were CMV-positive or
had a CMV-seropositive donor were given ganciclovir
5 mg/kg from day –8 until day –3. They then were
given acyclovir 10 mg/kg every 8 hours i.v. until dis-
charge. On discharge the vast majority were given
valacyclovir 2000 mg four times a day until day 210
[22]. CMV-negative donor/recipient pairs received
routine acyclovir prophylaxis. All patients were
screened weekly for CMV viremia until day 120 and
treated with ganciclovir or valganciclovir on detection
of CMV viremia.
At MDACC, lower doses of acyclovir or valacyclo-
vir were administered. Patients were screened biweekly
612 Biol Blood Marrow Transplant 15:610-617, 2009K. van Besien et al.forCMVantigenemiawithpreemptiveuseofganciclovir
in the event of a positive assay.
Other aspects of supportive care were very similar
between the 2 institutions and have been previously
reported.
Posttransplantation Evaluation
Disease relapse was defined as disease progression
from the best response. Death without disease progres-
sion was considered transplantation related. aGVHD
and cGVHD were scored and treated according to
standard criteria [23]. New definitions for aGVHD
and cGVHD were not yet used in these studies [24].
At both institutions donor lymphocyte infusions (DLIs)
were only used in case of overt disease persistence or
relapse, and never for mixed or declinining chimerism.
Patients requiring DLIs were considered treatment
failures.Table 1. Patient Characteristics
University of
Chicago
MD Anderson
Cancer Center P-Value
N 95 59
Median age (range) 54 (11-77) 55 (22-74) .4
AML/MDS/t-AML 70/13/12 39/9/11 .5
ASBMT Low/intermediate/high 33/13/49 16/6/37 .3
Prior transplant auto/allo 13/2 8/0 .7
Cytogenetic risk group
low/int/high
5/57/31† 2/35/22 .9
BM blast <5%/$5 48/47 34/25 .2
HCT-CI <3/>3 51/34 22/31* .05
Matched related/other 48/47 25/34 .3
BM/PB 3/92 26/33 <.01
Conditioning <.01
Alemtuzumab 95 0 <.01
Melphalan 100/140 0/95 13/46
ATG 0 20 <.01
GVHD Prophylaxis <.01
Tacrolimus 95 0
Tacrolimus/CsA + Methotrexate 0 59
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syn-
dromes; CsA, cyclosporine; GVHD, graft-versus-host disease; ATG,
antithymocyte globulin; BM, bone marrow; PB, peripheral blood;
ASBMT, American Society for Blood and Marrow Transplantation.
*Data missing in 6 patients.
†Data missing in 2 patients.Statistical Methods
Progression-free survival (PFS) (time to relapse or
death as a result of any cause), overall survival (OS),
and cumulative probability of aGVHD and extensive
cGVHDwere calculated using the Kaplan-Meier prod-
uct-limit estimate and expressed as probabilities with
a 95% confidence interval (CI) [25,26]. ForGVHD, pa-
tients who died without GVHD were censored at the
time of death, and cumulative probability at time t was
calculated as 1 – KM(t), where KM(t) is the Kaplan-
Meier estimate of remaining event-free at time t.
Cumulative incidence of disease progression with death
before progression as the competing risk [27], and cu-
mulative incidence of TRM with relapse of the original
disease as the competing risk were also calculated. (See
Chappell [28] orKlein et al [29] for a discussion of issues
related to the use of 1 – KM vs cumulative incidence.)
Univariate comparisons and multivariate analyses
used Cox proportional hazards regressions. Parameters
calculated in the univariate and multivariate analyses
included alemtuzumab use versus not (or its surrogate,
the treating institution); administration of rabbit ATG
versus not, disease status (low or intermediate risk
versus high risk as defined by ASBMT/CIBMTR cri-
teria), age, comorbidity scores (using the Seattle hema-
topoietic cell transplantation-specific comorbidity
[HCT-CI] index) [30], donor type (HLA-identical
related donor versus antigen-mismatched related or un-
related donor), and dose ofMel (100 versus 140mg/m2).
For the multivariate Cox models, independent variables
with P . 0.1 were excluded sequentially from the
models. Alemtuzumab use versus not was retained in
all steps of model-building because it was the main
effect of interest. The relative risks and the associated
P values of the remaining variables are reported. M.D.
Anderson data were updated until November 2007;
UC data until June 2008.RESULTS
Patient and Treatment Characteristics
Patient, disease, and treatment characteristics are
summarized in Table 1. The median age of patients
transplanted at both institutions was identical, and
there were no significant differences in disease type,
CIBMTR risk score, cytogenetic risk group as defined
in CALGB studies [31], proportion of patients with
increased blasts at conditioning, or proportion of
patients who had undergone a previous transplant.
Those at MDACC had a somewhat higher average
comorbidity score. Practically all patients at the UC
received donor PBSC; half of those at MDACC
received BM.Univariate and Multivariate Analysis of
Outcomes
The cumulative incidence of TRM, cumulative
incidence of relapse, PFS, andOS are shown inTable 2.
There are no significant differences in TRM, relapse
rate,DFS, andOSbetween the 2 groups.With amedian
follow-up for survivorsof 60months atMDACC(range:
25-86months) and of 37months at the UC (range: 3-77
months), 2-year survival is 41% (95% CI, 31%-53%)
for UC patients and 46% (95% CI, 35% to 53%) for
the MDACC patients. The survival curves are nearly
identical, and so are the PFS curves (Figures 1 and 2)
The cumulative incidence of grade III-IV aGVHD
and of cGVHD are shown in Figures 3 and 4.
Estimated rates are listed in Table 2. The cumulative
risk of aGVHD and particularly of cGVHD was
Table 2. Outcome Probabilities
U Chicago MDACC
Outcome Probability (95% CI) Probability (95% CI) P-Values
Treatment-related mortality* .25
Day 100 11.5% (6.1-18.9) 16.9 (8.6-27.6)
1 year 24.6% (16.3-33.7) 28.8 (17.8-40.7)
Relapse* .24
1 year 23.7% (15.6-32.9) 20.3% (11.1-31.5)
Progression free survival† .95
2 years 33% (23.5-42.7) 35.6% (23.7-47.7)
Overall survival† .92
2 years 40.5% (30.2-50.6) 45.7% (32.8-57.8)
Acute GVHD grade II-IV †
2 years 23.3 % (15.7-33.8) 58.1 % (45.2-71.6) <.01
Acute GVHD grade III-IV†
2 years 8.6% (4.2-17.2) 16.5% (8.9-29.4) .08
Chronic GVHD†
2 years 16.0% (8.1-30.2) 78.4 % (62.6-90.7) <.01
*Cumulative incidence
†Kaplan-Meier estimate
CI indicates confidence interval; GVHD, graft-versus-host disease.
*To compare the cumulative incidence curves we used the Gray’s test.
†Log rank test was used to compare the Kaplan Meier curves.
Biol Blood Marrow Transplant 15:610-617, 2009 613Fludarabine-Melphalan Conditioning for AML and MDSmuch higher among patients receiving transplant at
MDACC. More than half of the surviving patients at
MDACC have cGVHD in contrast to only 2 of 37
patients at the UC.
Multivariate Analysis
The relative risks and P values of the remaining
independent variables in the multivariate Cox regres-
sions with stepwise model selection are listed in Table
3. TRM was lower in recipients of matched related
donor transplants (P\ .01). A reduction in TRM in
recipients of an alemtuzumab-prepared transplant was
not statistically significant (Figure 5). Disease progres-
sion was increased with lower doses of Mel, and in-
creased in patients with high-risk disease. Receiving an
alemtuzumab-prepared transplant was associated with
a trend toward higher relapse risk, but this association
was not statistically significant (Figure 6).
High-risk leukemia or MDS and receiving a mis-
matched or unrelated donor transplant were the onlyFigure 1. Survival.predictors for DFS and OS. Transplant conditioning
or GVHD prophylaxis had no significant impact.
The risk for grade II-IV aGVHD was increased
with unrelated donor transplant (P 5 .02) and was
decreased with alemtuzumab prepared transplant (rel-
ative risk [RR] 5.45, P\ .01). The risk for grade III-IV
aGVHD was also reduced with the use of alemtuzu-
mab, but this reduction was not statistically significant
(RR 2.9, P 5 .08) The risk for cGVHD was reduced
more than 6-fold with an alemtuzumab-prepared
transplant (RR 6.6, P\ .01)DISCUSSION
Allogeneic transplantation is a curative treatment
forpatientswithadvanced leukemiaorMDS.Complica-
tions of intensive myeloablative conditioning, relapse,
and lack of donors have long limited its application to
younger patients in excellent condition. Recent im-
provements, including better selection of unrelated
donors [32], better management and prevention of
infectious complications [33,34], the development of
novel conditioning regimens [11,35,36], as well as
newer methods of GVHD prophylaxis have generated
considerable interest in extending the use of transplant
to older and less fit patients [1-3].
The Flu 1Mel regimen initially developed in the
mid nineties cures a fraction of patients and has been
widely adopted [4-7]. PBSC are commonly used with
this regimen in an attempt to hasten immune reconsti-
tution, but have been the cause of a high incidence of
extensive cGVHD, which is associated with consider-
able chronic morbidity and mortality [37]. To reduce
the incidence of cGVHD, several centers have used
in vivo alemtuzumab with the Flu1Mel conditioning
Figure 2. Progression-Free Survival.
Figure 4. Chronic GVHD.
614 Biol Blood Marrow Transplant 15:610-617, 2009K. van Besien et al.regimen instead of posttransplant MTX [17-20]. This
regimen results in a very low incidence of aGVHD and
cGVHD, probably because of alemtuzumab’s differ-
ential effects on host- and donor-antigen presenting
cells (APCs) [38,39], as well as on B and T cells, both
of which play important effector roles in cGVHD
[40]. But many are concerned that the use of alemtuzu-
mab will lead to unacceptable rates of disease recur-
rence and to profound immunosuppression and fatal
opportunistic infections. To evaluate the overall im-
pact of alemtuzumab on outcome of transplantation
in AML and MDS, we compared the outcome of pa-
tients treated on the UC protocol with alemtuzu-
mab-based GVHD prophylaxis, with a cohort of
patients treated and previously reported from
MDACC who received almost identical doses of che-
motherapy. All MDACC patients received MTX and
tacrolimus, and none received alemtuzumab. Patient
and disease characteristics were remarkably similar be-
tween the 2 institutions, with nearly half of the patients
undergoing unrelated donor transplantation and many
patients with advanced hematologic malignancies.
The median age of 54 years at both institutions reflects
current patterns of patient selected for allogeneic
transplantation at U.S. hospitals [1].
Themost striking difference between the 2 cohorts
is the much reduced incidence of GVHD in patientsFigure 3. Acute GVHD.receiving alemtuzumab-based conditioning. This is
particularly true for cGVHD, which is nearly 6-fold re-
duced. This observation is consistent with prior studies
of T cell-depleted transplantation using CAMPATH
formulations, which indicate a very effective abroga-
tion of cGVHD. The effective prevention of GVHD
by in vivo T cell depletion did not lead to an increased
incidence of opportunistic infections. Indeed, with
aggressive CMV prophylaxis, the incidence of CMV
disease was exceedingly low after alemtuzumab condi-
tioning, and other opportunistic infections were rare
and often manageable. These observations are also
consistent with those from the UK consortium, who
report a high incidence of CMV viremia, but few
instances of CMV disease [19].
Although aGVHD and cGVHD have been typi-
cally associated with decreased recurrence rates, we
showed a nonsignificant increase in recurrence rates
with alemtuzumab. It remains debatable how impor-
tant graft-versus-leukemia (GVL) effects are for over-
all outcome in acute leukemia and MDS [41-46]. The
fact that 50% to 60% of patients with early-stage AML
survive free of disease after alemtuzumab-based condi-
tioning or after in vitro T cell depletion, with a very
low incidence of cGVHD suggests that overt GVHD
is not a necessary or desirable component of allogeneic
transplantation for AML or MDS [17,20,42-47]. Of
interest, lower doses of Mel used in 13 of the MDACC
patients was associated with increased risk of disease
recurrence in multivariate analysis. This observation
lends further credence to the importance of dose inten-
sity in allogeneic transplant for AML and MDS. The
MDACC group previously compared the outcome of
Flu-cytarabine-idarubicin (nonablative) with that after
Flu1Mel (RIC) and found better disease control with
the more dose-intense regimen [4]. In a previous study
of a small cohort of older unrelated donor recipients
they found a 54% survival after Flu1Mel-180 condi-
tioning compared to 14%with Flu1Mel-140 [3]. It is
noteworthy that, in contrast to many other studies,
none of the patients in either cohort received
Table 3. Multivariate Analysis of Treatment-Related Mortal-
ity, Relapse, Progression-Free Survival, and Overall Survival
Variables
Relative Risk
(95% CI) P-Value
Treatment related mortality
Main effect:
U Chicago 1.00/Referent .3
MDACC 1.44 (0.7-2.9)
Other significant covariates:
Related and matched 0.37 (0.18-0.76) <.01
Relapse
Main effect:
U Chicago 1.00/Referent
MDACC 0.56 (0.3-1.05) .07
Other significant covariates:
Dose 0.2 (0.05-0.75) .01
Risk group 2.67 (1.7-4.1) <.01
Progression-free survival
Main effect:
U Chicago 1.00/Referent
MDACC 0.8 (0.5-1.3) .3
Other significant covariates:
Risk Group 2.06 (1.5-2.8) <.01
Related and matched 0.6 (0.4-0.9) .03
Overall survival
Main effect:
U Chicago 1.00/Referent
MDACC 0.9 (0.56-1.43) .6
Other significant covariates:
Risk group 2.00 (1.45-2.75) <.01
Related and matched 0.6 (0.4-0.9) .02
Acute GVHD Grade II-IV
Main effect:
UC 1.00/Referent
MDACC 5.45 (2.8-10.3) <.01
Other significant covariates:
Related and matched 0.5 (0.28-0.93) .02
Acute GVHD Grade III-IV
Main effect:
U Chicago 1.00/Referent
MDACC 2.9 (0.87-9.5) .08
No significant covariates
Chronic GVHD
Main effect:
UC 1.00/Referent
MDACC 6.6 (2.8-15.4) <.01
No significant covariates
MDACC indicates M.D. Anderson Cancer Center; GVHD, graft-versus-
host disease.
Figure 5. Cumulative Probability of Treatment-Related Mortality.
Figure 6. Cumulative probability of Disease Recurrence.
Biol Blood Marrow Transplant 15:610-617, 2009 615Fludarabine-Melphalan Conditioning for AML and MDSprophylactic DLI for mixed or declining chimerism,
thus avoiding any potential effect of adoptive cellular
therapies on rates of disease recurrence.
OS and PFS are nearly identical between the alem-
tuzumab- and nonalemtuzumab-prepared patients. As
in other studies, disease-related factors (summarized
here as the risk group) are themost important determi-
nants of OS and PFS. Our data have several limitations
related to the retrospective study design. The patients
at MDACC were transplanted several years earlier,
and high-resolution HLA-typing for class I loci was
not yet utilized. This might have had an impact on
the incidence of GVHD and of TRM in unrelated
donor recipients. Similarly, supportive care particu-
larly relating to antifungal prophylaxis has evolved
considerably, and this may have affected TRM, butless likelyGVHD. It is also possible that there are imbal-
ances in other latent variables that remain unrecognized.
With these caveats in mind, our overall results
illustrate the persisting problems of allogeneic trans-
plantation in AML and MDS, but also provide some
clues for future research. Approximately one-third of
patients obtain durable remissions, but patients with
advanced disease are particularly prone to relapse. The
use of alemtuzumab has, in our opinion, advantages
over MTX-based GVHD prophylaxis, particularly in
patients with less advanced AML and MDS, because a
higher percentage of patients survive without cGVHD,
and rates of disease recurrence are minimally, if at all,
affected. This is not the case in all diseases. Similar
results have been reported in patients with lymphoma
[48], but the UK group in particular has pointed out an
increased risk for TRM and opportunistic infections in
chronic lymphocytic leukemia (CLL) patients who are
prepared for transplant with an alemtuzumab-based
regimen, probably because of excessive preexisting
616 Biol Blood Marrow Transplant 15:610-617, 2009K. van Besien et al.immunosuppression [49]. Others have found that
CML patients and myeloma patients also have a very
high risk for disease recurrence [50,51]. Similarly,
not all methods of T cell depletion have equal effects
on cGVHD. Thymoglobulin-based T cell depletion
reduces cGVHD in a fashion similar to alemtuzumab
[52], but T cell depletion with the monoclonal 10B9
or with counterflow elutriation does not [53].
The limitations of current conditioning regimens
may be addressed in a variety of ways. Selection of
patients with less advanced disease, that is, earlier in
the course of the disease, represents an attractive
option. There are, however, major logistical obstacles
to early transplantation, and it is likely that many
patients with refractory disease will continue to be
referred. Immune manipulations as well as modifica-
tions of chemotherapeutic regimens may both be stud-
ied to render allogeneic transplantationmore effective,
and may represent complementary approaches. The
development of intensified or more effective drug
regimens using optimized dosing schedules and novel
drugs such as i.v. Bu, treosulfan, or more recently
clofarabine, therefore remain an area of major interest.
Decreasing GVHD prophylaxis or its duration is
a widely used tool for inducing GVL effects, but can
result in unacceptable rates of GVHD. Abrogation of
GVHD by in vivo or in vitro T cell depletion may be
further fine tuned, for example, by changing the inten-
sity of T cell depletion. Infusions of small doses of
donor lymphocytes, or of lymphocyte subsets (regula-
toryT cell [Treg] depleted,CD8 depleted, natural killer
[NK] cells) may be studied in high-risk patients after
transplantation. Other approaches, such as immunosti-
mulation with interferon, interleukin 2 (IL2), or other
immunomodulators may also be of interest.ACKNOWLEDGMENTS
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